Weekly Digest – February 2025 Weekly Digest – February 2025 14 Feb 2025: 1st Trop-2 ADC Trodelvy expands indication to metastatic HR+/HER2- breast cancer Trodelvy (Sacituzumab govitecan) received expanded approval in Korea to treat metastatic HR+/HER2- breast cancer resistant to […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Corbus posts first US data on challenger to Pfizer’s ADC Padcev Corbus Pharmaceuticals’ western trial of its ADC showed a 27% response rate, aligning with prior Chinese […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Radiance Biopharma enters exclusive license for ROR-1 targeted Antibody Drug Conjugate (ADC) Radiance Biopharma has signed an exclusive license agreement with CSPC Megalith for the development and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Sonnet BioTherapeutics unveils ADC Platform with promising preclinical results and partnership opportunities Sonnet BioTherapeutics announced its ADC platform, leveraging its FHAB domain for flexible payload capacity and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 20 Feb 2025: Myris Therapeutics is developing ultra-high DAR ADCs to enable novel precision medicine treatments for cancer Myris Therapeutics, formerly BioHybrid Solutions, has emerged from stealth with a focus […]
